Literature DB >> 33821928

Minimal-Contact Versus Standard Cognitive Behavioral Therapy for Irritable Bowel Syndrome: Cost-Effectiveness Results of a Multisite Trial.

Laura J Dunlap1, James Jaccard2, Jeffrey M Lackner3.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is a common, often disabling gastrointestinal (GI) disorder for which there is no satisfactory medical treatment but is responsive to cognitive behavior therapy (CBT).
PURPOSE: To evaluate the costs and cost-effectiveness of a minimal contact version of CBT (MC-CBT) condition for N = 145 for IBS relative to a standard, clinic-based CBT (S-CBT; N = 146) and a nonspecific comparator emphasizing education/support (EDU; N = 145).
METHOD: We estimated the per-patient cost of each treatment condition using an activity-based costing approach that allowed us to identify and estimate costs for specific components of each intervention as well as the overall total costs. Using simple means analysis and multiple regression models, we estimated the incremental effectiveness of MC-CBT relative to S-CBT and EDU. We then evaluated the cost-effectiveness of MC-CBT relative to these alternatives for selected outcomes at immediate posttreatment and 6 months posttreatment, using both an intent-to-treatment and per-protocol methodology. Key outcomes included scores on the Clinical Global Impressions-Improvement Scale and the percentage of patients who positively responded to treatment.
RESULTS: The average per-patient cost of delivering MC-CBT was $348, which was significantly less than the cost of S-CBT ($644) and EDU ($457) (p < .01). Furthermore, MC-CBT produced better average patient outcomes at immediate and 6 months posttreatment relative to S-CBT and EDU (p < .01). The current findings indicated that MC-CBT is a cost-effective option relative to S-CBT and EDU.
CONCLUSION: As predicted, MC-CBT was delivered at a lower cost per patient than S-CBT and performed better over time on the primary outcome of global IBS symptom improvement. © Society of Behavioral Medicine 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID ∙ ICER; Chronic pain; Comparative effectiveness; Economic analysis; Value-based care

Mesh:

Year:  2021        PMID: 33821928      PMCID: PMC8489303          DOI: 10.1093/abm/kaaa119

Source DB:  PubMed          Journal:  Ann Behav Med        ISSN: 0883-6612


  34 in total

1.  Representing uncertainty: the role of cost-effectiveness acceptability curves.

Authors:  E Fenwick; K Claxton; M Sculpher
Journal:  Health Econ       Date:  2001-12       Impact factor: 3.046

2.  Arbitrary metrics: implications for identifying evidence-based treatments.

Authors:  Alan E Kazdin
Journal:  Am Psychol       Date:  2006-01

Review 3.  Irritable Bowel Syndrome.

Authors:  Alexander C Ford; Brian E Lacy; Nicholas J Talley
Journal:  N Engl J Med       Date:  2017-06-29       Impact factor: 91.245

4.  Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.

Authors:  Hazel Everitt; Sabine Landau; Paul Little; Felicity L Bishop; Gillian O'Reilly; Alice Sibelli; Rachel Holland; Stephanie Hughes; Sula Windgassen; Paul McCrone; Kim Goldsmith; Nicholas Coleman; Robert Logan; Trudie Chalder; Rona Moss-Morris
Journal:  Health Technol Assess       Date:  2019-04       Impact factor: 4.014

5.  Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Gregory D Gudleski; Laurie Keefer; Susan S Krasner; Cathrine Powell; Leonard A Katz
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-17       Impact factor: 11.382

6.  The promise and pitfalls of the internet for cognitive behavioral therapy.

Authors:  Gerhard Andersson
Journal:  BMC Med       Date:  2010-12-07       Impact factor: 8.775

Review 7.  Design of treatment trials for functional gastrointestinal disorders.

Authors:  E Jan Irvine; William E Whitehead; William D Chey; Kei Matsueda; Michael Shaw; Nicholas J Talley; Sander J O Veldhuyzen van Zanten
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

8.  Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

Authors:  D A Drossman; W D Chey; J F Johanson; R Fass; C Scott; R Panas; R Ueno
Journal:  Aliment Pharmacol Ther       Date:  2008-11-04       Impact factor: 8.171

Review 9.  Role of brain imaging in disorders of brain-gut interaction: a Rome Working Team Report.

Authors:  Emeran A Mayer; Jennifer Labus; Qasim Aziz; Irene Tracey; Lisa Kilpatrick; Sigrid Elsenbruch; Petra Schweinhardt; Lukas Van Oudenhove; David Borsook
Journal:  Gut       Date:  2019-06-07       Impact factor: 23.059

10.  Psychological therapies for the management of chronic pain (excluding headache) in adults.

Authors:  Amanda C de C Williams; Emma Fisher; Leslie Hearn; Christopher Eccleston
Journal:  Cochrane Database Syst Rev       Date:  2020-08-12
View more
  3 in total

Review 1.  Pain in irritable bowel syndrome: Does anything really help?

Authors:  Joelle BouSaba; Wassel Sannaa; Michael Camilleri
Journal:  Neurogastroenterol Motil       Date:  2021-12-03       Impact factor: 3.960

2.  Study protocol and methods for Easing Pelvic Pain Interventions Clinical Research Program (EPPIC): a randomized clinical trial of brief, low-intensity, transdiagnostic cognitive behavioral therapy vs education/support for urologic chronic pelvic pain syndrome (UCPPS).

Authors:  Jeffrey M Lackner; James Jaccard; Brian M Quigley; Tova S Ablove; Teresa L Danforth; Rebecca S Firth; Gregory D Gudleski; Susan S Krasner; Christopher D Radziwon; Alison M Vargovich; J Quentin Clemens; Bruce D Naliboff
Journal:  Trials       Date:  2022-08-13       Impact factor: 2.728

3.  A Coached Digital Cognitive Behavioral Intervention Reduces Anxiety and Depression in Adults With Functional Gastrointestinal Disorders.

Authors:  Eva Szigethy; Aylin Tansel; Alexa N Pavlick; Maria A Marroquin; Catherine D Serio; Valerie Silfee; Meredith L Wallace; Michael J Kingsley; David J Levinthal
Journal:  Clin Transl Gastroenterol       Date:  2021-12-07       Impact factor: 4.488

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.